Related references
Note: Only part of the references are listed.Development and dynamics of robust T-cell responses to CML under imatinib treatment patients
Christiane I-U. Chen et al.
BLOOD (2008)
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia:: Implications for defining sensitivity in minimal residual disease
David M. Ross et al.
CLINICAL CHEMISTRY (2008)
Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia
Elia Mattarucchi et al.
GENES CHROMOSOMES & CANCER (2008)
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria
Susan Branford et al.
CLINICAL CANCER RESEARCH (2007)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
Ingo Roeder et al.
NATURE MEDICINE (2006)
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
Jaspal Kaeda et al.
BLOOD (2006)
Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
J Goldman et al.
LEUKEMIA & LYMPHOMA (2006)
Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation
T Lange et al.
LEUKEMIA (2005)
Dynamics of chronic myeloid leukaemia
F Michor et al.
NATURE (2005)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
MC Muller et al.
LEUKEMIA (2003)
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
A Burchert et al.
BLOOD (2003)
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
JJ Molldrem et al.
NATURE MEDICINE (2000)
Share Paper
